ストックスクリーナーアプリを入手
0.628
7.17%
0.042
アフターアワーズ：
.63
0.002
+0.32%
前日終値:
$0.586
開ける：
$0.6
24時間の取引高:
1.37M
Relative Volume:
2.74
時価総額：
$54.18M
収益：
当期純損益:
$-50.21M
株価収益率:
-0.3296
EPS:
-1.9053
ネットキャッシュフロー:
$-16.61M
1週間 パフォーマンス:
-18.37%
1か月 パフォーマンス:
-11.24%
6か月 パフォーマンス:
-64.72%
1年 パフォーマンス:
-51.69%
1日の値動き範囲:
$0.551
$0.666
1週間の範囲:
$0.5401
$0.81
52週間の値動き範囲:
$0.5401
$2.18
Rein Therapeutics Inc Stock (RNTX) Company Profile
Compare RNTX vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
0.628 | 54.18M | 0 | -50.21M | -16.61M | -1.9053 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-22 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2017-07-24 | 開始されました | BofA/Merrill | Buy |
| 2017-07-24 | 開始されました | Jefferies | Buy |
| 2017-07-24 | 開始されました | William Blair | Outperform |
Rein Therapeutics Inc (RNTX) 最新ニュース
Rein Therapeutics Inc (RNTX-Q) Stock Price and News - The Globe and Mail
Rein Therapeutics (RNTX) Ticks Up 1.37% to $0.80 as Traders Eye ResistanceFibonacci Retracement - dars.gov.et
Rein Therapeutics at cantor global healthcare: ipf push gains traction By Investing.com - Investing.com South Africa
Rein Therapeutics at cantor global healthcare: ipf push gains traction By Investing.com - Investing.com Canada
Rein Therapeutics at cantor global healthcare: ipf push gains traction - Investing.com
Rein Therapeutics at cantor global healthcare: ipf push gains traction - Investing.com India
RNTX: LTI-03 advances in Phase 2 IPF trials after promising safety and biomarker results - TradingView
We're Hopeful That Rein Therapeutics (NASDAQ:RNTX) Will Use Its Cash Wisely - simplywall.st
Rein Therapeutics Highlights LTI-03 Progress in IPF - TipRanks
Rein Therapeutics publishes LTI-03 presentation; Phase 1b biomarker signals and Phase 2 RENEW now enrolling - TradingView
Inhaled IPF drug from Rein Therapeutics (NASDAQ: RNTX) shows early safety data - Stock Titan
A study of an inhaled treatment for lung scarring will be presented Sept. 8 in Barcelona. - Stock Titan
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Rein Therapeutics to Present at Upcoming September Investor Conferences - Yahoo Finance
Here's Why You Should Add RNTX Stock to Your Portfolio Now - The Globe and Mail
Here's Why You Should Add RNTX Stock to Your Portfolio Now - Eastern Progress
Rein Therapeutics Receives Nasdaq Delisting Notice Over Bid Price - The Globe and Mail
Rein Therapeutics Receives Nasdaq Delisting Notice Over Bid Price - TipRanks
Rein Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Rein Therapeutics Inc (NASDAQ: RNTX) Stock Price, News & Analysis - kalkine.ca
Rein (RNTX) Quarter in Focus: The Available Earnings Metric Delivers a Beat on the Day; Post-Report: Shares Move 0.88% Higher in the Current UpdateGuidance Accuracy Score - vinanet.vn
Rein Therapeutics receives FDA fast track for IPF drug LTI-03 - Investing.com Nigeria
Rein Therapeutics receives FDA fast track for IPF drug LTI-03 - Investing.com Australia
Rein Therapeutics receives FDA fast track for IPF drug LTI-03 - Investing.com Canada
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - The Manila Times
Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis - TradingView
FDA grants Fast Track designation to inhaled treatment for lung disease with 3-to-5-year median survival - Stock Titan
Equities Analysts Set Expectations for RNTX FY2026 Earnings - MarketBeat
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - Yahoo Finance
Rein Therapeutics Inc (NASDAQ: RNTX) Stock Price, News & Analysis - Kalkine
What is HC Wainwright's Estimate for RNTX FY2030 Earnings? - MarketBeat
RNTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Rein Therapeutics (NASDAQ:RNTX) Given "Buy" Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy on Rein Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on Rein Therapeutics stock By Investing.com - Investing.com UK
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates as Stock Climbs 2.35%Tech Earnings Analysis - vinanet.vn
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates as Stock Climbs 2.35%Revenue Report - dars.gov.et
Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results - MarketBeat
Rein Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Rein Therapeutics (RNTX) Holds at $0.79 as Range-Bound Trading PersistsVWAP Bounce - vinanet.vn
Rein Therapeutics raises $44.3M to fund lung-disease drug trial - Dealroom
Rein Therapeutics Raises $44.3 Million in Public Offering - Minichart
Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Rein Therapeutics Surpasses 25% Enrollment in Phase 2 RENEW Trial of LTI-03 for IPF, Completes $57.5 Million Public Offering - Quiver Quantitative
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Press Release: Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Rein Therapeutics 2Q 2026: Revenue $0 Net loss $6.4M, EPS $(0.10) — 10-Q Summary - TradingView
RNTX: Q2 net loss narrowed, liquidity strengthened, and Phase 2 LTI-03 trial remains on track - TradingView
Rein Therapeutics Inc (RNTX) 財務データ
収益
当期純利益
現金流量
EPS
Rein Therapeutics Inc (RNTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| VON RICKENBACH JOSEF H | Director |
May 27 '26 |
Buy |
1.07 |
4,500 |
4,819 |
62,514 |
| VON RICKENBACH JOSEF H | Director |
May 22 '26 |
Buy |
1.05 |
15,950 |
16,708 |
34,824 |
| VON RICKENBACH JOSEF H | Director |
May 21 '26 |
Buy |
1.04 |
3,420 |
3,564 |
18,874 |
| WINDSOR JAMES BRIAN | See Remarks |
Apr 30 '26 |
Buy |
1.00 |
25,000 |
25,000 |
27,046 |
| Voss Capital, LP | 10% Owner |
Nov 14 '25 |
Buy |
1.22 |
104,183 |
127,593 |
926,441 |
| Voss Capital, LP | 10% Owner |
Oct 28 '25 |
Buy |
1.39 |
178,392 |
247,965 |
500,000 |
| Voss Capital, LP | 10% Owner |
Oct 27 '25 |
Buy |
1.37 |
97,482 |
133,544 |
822,258 |
| Voss Capital, LP | 10% Owner |
Oct 24 '25 |
Buy |
1.39 |
30,176 |
41,957 |
729,616 |
1.35%
大文字化:
|
ボリューム (24 時間):